Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2025)

Historic Finished Goods for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $2.6 million.

  • Phathom Pharmaceuticals' Finished Goods rose 13793.42% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 13793.42%. This contributed to the annual value of $1.5 million for FY2024, which is 12859.35% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Finished Goods is $2.6 million, which was up 13793.42% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Finished Goods registered a high of $2.6 million during Q3 2025, and its lowest value of $647000.0 during Q4 2023.
  • Moreover, its 3-year median value for Finished Goods was $1.3 million (2024), whereas its average is $1.5 million.
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Finished Goods showed a top increase of 17727.27% in 2025 and a maximum decrease of 11088.02% in 2025.
  • Quarter analysis of 3 years shows Phathom Pharmaceuticals' Finished Goods stood at $647000.0 in 2023, then surged by 128.59% to $1.5 million in 2024, then soared by 76.0% to $2.6 million in 2025.
  • Its Finished Goods was $2.6 million in Q3 2025, compared to $2.4 million in Q2 2025 and $1.7 million in Q1 2025.